Skip to main content

Table 3 Quality of life scores before and 6 months after switch from IV or IM HBIG to SC HBIG

From: Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation

Domain

N

Baseline

End of study

P value*

Effect size

ITaLi-Q

 Side effects

83

27.9 ± 27.5

5.5 ± 10.6

< 0.0001

0.81

 Side effects impact

82

12.6 ± 19.0

2.3 ± 6.7

< 0.0001

0.54

 Negative feelings

81

19.8 ± 25.5

5.7 ± 10.7

< 0.0001

0.55

 Positive feelings

81

86.3 ± 18.3

87.0 ± 22.5

0.36

0.08

 Flexibility

79

31.8 ± 25.8

17.0 ± 14.9

< 0.0001

0.57

 Support

75

52.3 ± 36.7

32.0 ± 27.6

< 0.0001

0.55

 Need for support

80

38.7 ± 42.1

7.7 ± 19.0

< 0.0001

0.74

 Satisfaction

80

59.6 ± 22.0

84.1 ± 17.1

< 0.0001

1.11

SF-36

 Physical functioning

85

76.2 ± 22.8

78.2 ± 24.0

0.05

0.09

 Role physical

81

64.8 ± 41.0

75.0 ± 39.7

0.03

0.25

 Pain

86

71.7 ± 24.6

83.9 ± 23.1

<.0001

0.50

 General health

84

51.8 ± 24.0

50.8 ± 23.6

0.93

0.04

 Vitality

83

57.4 ± 20.3

58.6 ± 18.2

0.13

0.06

 Social functioning

86

73.8 ± 22.7

82.8 ± 20.9

< 0.0001

0.40

 Role emotional

81

66.7 ± 42.1

78.6 ± 37.4

0.005

0.28

 Mental health

83

66.0 ± 19.3

67.0 ± 17.9

0.39

0.05

 Physical component summary score

75

45.7 ± 8.9

48.1 ± 8.3

0.002

0.27

 Mental component summary score

75

46.3 ± 10.7

48.2 ± 9.5

0.007

0.18

  1. HBIG hepatitis B immunoglobulin, IM intramuscular, ITaLi-Q Immunoglobulin Therapy after Liver transplantation Questionnaire, IV intravenous, SC subcutaneous
  2. * Wilcoxon signed ranks test